Fresh analysis reveals that people who come off popular weight-loss injections like Wegovy and Mounjaro may regain shed pounds at a significantly accelerated pace than those who end traditional lifestyle plans.
Findings released in a leading health publication shows that while obese individuals often shed a large proportion of their body weight while on the medication, the mass is regained at an estimated rate of nearly a kilo each month once they quit.
"Individuals purchasing these treatments need to be informed of the danger of rapid rebound weight gain when the medication concludes," stated researcher Dr. Susan Jebb.
This pace of recovery implies a return to original weight within about 18 months.
Comparing Therapies
The research, which reviewed dozens of trials involving thousands of patients, contrasted the outcomes of GLP-1 agonists with conventional dieting.
Scientists note that individuals who lose weight through diet and exercise generally have a more gradual weight regain—perhaps 0.1 kg a month—post-intervention.
Explaining the Quick Rebound
Nutrition scientists propose the way of the jabs is key to understanding the amplified weight return.
GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.
"Artificially providing GLP-1 concentrations far above than the body's typical production could lead to the system to produce less of its own natural hormone, and may also diminish responsiveness to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this medication results in appetite is no longer kept in check, making overeating much more probable."
A Lifelong Issue?
The NHS advise the injections for individuals with weight-linked health risks, alongside recommended diet and exercise modifications.
A number of clinicians contend that, due to the high risk of weight regain, the therapy should be considered ongoing.
This opinion is echoed by pharmaceutical companies, who say that the results "highlight the persistent character of obesity," comparing it to managing diseases like hypertension.
Patient Experiences
Individuals who have discontinued the jabs describe a sudden resurgence of appetite.
"It was like a trigger flipping and you're instantly ravenous," said one woman.
The struggle is worsened if users have not developed permanent lifestyle or habit changes during treatment.
Significant Interest
Survey data indicate that a significant number of adults in the UK have used weight-loss jabs in the past year, with interest remaining high.
- Adoption is higher among females than men.
- The middle-aged demographic shows the greatest usage rates.
- Many access the medications through private prescriptions rather than the NHS.
In conclusion, researchers caution that while GLP-1 drugs are effective tools for shedding pounds, they are not a standalone fix and maintained weight loss hinges on integrated behavioural support.
